Acta Scientific Otolaryngology (ASOL) (ISSN: 2582-5550)

Case Report Volume 4 Issue 7

Neurofibromatosis with Conductive Hearing Loss - A Rare Presentation

Sanyukta Chakravorty1*, Sumit Sharma2, Rashmi Nambiar1 and Mahesh Mishra1

1Postgraduate Junior Resident Second Year, Department of E.N.T., Mayo Institute of Medical Sciences, Barabanki, UP, India
2Professor and Head, Department of E.N.T., Mayo Institute of Medical Sciences, Barabanki, UP, India

*Corresponding Author: Sanyukta Chakravorty, Postgraduate Junior Resident Second Year, Department of E.N.T., Mayo Institute of Medical Sciences, Barabanki, UP, India.

Received: June 14, 2022; Published: June 28, 2022


Background: Neurofibromatosis (NF1) is an autosomal dominant, multisystem disorder. Trials are ongoing to discover and test medical treatments for the various manifestations of NF1, primarily plexiform neurofibromas, learning disabilities, and optic pathway gliomas, which are a significant cause of morbidity in these patients. Penetrance approaches 100% by age 20; if the patient has the mutation, he or she will exhibit manifestations, although expressivity is highly variable.

Objective: This case highlights the importance of early diagnosis and management in case of plexiform neurofibromatosis, to rectify conductive hearing loss and for aesthetic corrections.

Methods: Here we report a case of 22 year old female with right side conductive hearing loss with growth present over right external auditory canal.

Result: Computed tomography and histopathology revealed that this is case of plexiform neurofibromatosis which was managed by surgical excision.

Conclusion: By the help of this study, we emphasized the role of early intervention and treatment in case of plexiform neurofibromatosis to control its further growth and spread.

Keywords: Plexiform Neurofibromatosis, Cafe-au-lait Spots; Axillary Freckling; Mustarde’s Suture


  1. Crowe FW., et al. “A Clinical, Pathologicala and Genetic Study of Multiple Neurofibromatosis”. Springfield, IL: Charles C Thomas (1956).
  2. Brems H., et al. “Germline loss-of-function mutations in SPRED1 cause a neurofibromatosis 1-like phenotype”. Nature Genetics 39 (2007): 1120-1126.
  3. Korf BR and Rubenstein AE. “Neurofibromatosis: A Handbook for Patients, Families, and Health Care Professionals. 2nd New York: Thieme (2005).
  4. Riccardi VM and Lewis RA. “Penetrance of von Recklinghausen neurofibromatosis: a distinction between predecessors and descendants”. American Journal of Human Genetics 42 (1998): 284-289.
  5. Theos A and Korf BR. “Pathophysiology of Neurofibromatosis Type 1”. Annals of Internal Medicine 144 (2006): 842-849.
  6. Von Recklinghausen F: Über die Multiplen Fibrome der Haut und Ihre Beziehungenzu Multiplen Neuromen. Berlin, August Hirschwald (1882).
  7. National Institutes of Health Consensus Development Conference: Neurofibromatosis: Conference statement. Archives of Neurology 45 (1988): 575-578.
  8. Wallace M., et al. “Type 1 neurofibromatosis gene: Identification of a large transcript disrupted in three NF1 patients”. Science 249 (1990): 181-186.
  9. Cawthon R., et al. “A major segment of the neurofibromatosis type 1 gene: cDNA sequence, genomic structure, and point mutations”. Cell 62 (1990): 193-201.
  10. Gutmann D., et al. “The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2”. JAMA 278 (1997): 51-57.
  11. DeBella K., et al. “Use of the National Institutes of Health criteria for diagnosis of neurofibromatosis 1 in children”. Pediatrics 105 (2000): 608-614.
  12. Goldberg Y., et al. “Neurofibromatosis type 1— An update and review for the primary pediatrician”. Clinical Pediatrics (Phila) 35 (1996): 545-561.
  13. Fortman BJ., et al. “Neurofibromatosis type 1: a diagnostic mimicker at CT”. Radiographics 21 (2001): 60112.
  14. Rasmussen SA, ., et al. “Mortality in neurofibromatosis 1: an analysis using U.S. death certificates”. American Journal of Human Genetics 68 (2001): 1110-1118.


Citation: Sanyukta Chakravorty., et al. “Neurofibromatosis with Conductive Hearing Loss - A Rare Presentation".Acta Scientific Otolaryngology 4.7 (2022): 89-92.


Copyright: © 2022 Sanyukta Chakravorty., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


Acceptance rate34%
Acceptance to publication20-30 days
Impact Factor0.871

Indexed In

News and Events

  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is May 30, 2024.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of "Best Article of the Issue"
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.

Contact US